NCT05466448已完成1 期
An Open Label Phase 2 Study to Compare the Pharmacokinetics, Efficacy and Safety of RZL-012 in Chinese Subjects Seeking Submental Fat Reduction vs. Non-Chinese Subjects Seeking Submental Fat Reduction
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Pharmacokinetics Measure - Drug Concentration in the Blood (ng/mL)
研究概览
简要总结
This is a Phase 2, open label study that will consist of a screening period, baseline period in which subjects will receive a single treatment session and a follow-up period. The single treatment session will consist of multiple injections of RZL-012 into the submental area under the chin. Blood samples will be collected from all subjects for PK analyses in the first 30 hours after dosing. Subjects will thereafter be monitored for safety and efficacy for at least 84 days.
详细描述
• RZL-012 (concentration of injected solution 50 mg/mL RZL-012) of 7.5 mg/0.15 mL/injection point that results in a total dose/volume of 240±30mg mg/4.8±0.6 mL RZL-012
Subjects treated with RZL-012 will undergo a single treatment session with 32±4 injections. The maximal number of injections will be 36 with maximal dose of 270 mg RZL-012 .
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is a male or female subject between the ages of 18 and 65 years, inclusive.
- •Has body mass index (BMI) between >22 kg/m2 and <40 kg/m
- •If enrolled for Chinese arm, subjects have to be ethnically pure, i.e., Chinese passport holders with all four grandparents being Chinese.
- •Has a SMF bulge that is contiguous and fits to 32±4 injections sites according to a grid with 1 centimeter (cm) distance between injection points.
- •Has grade 3 to 4 of SMF as rated by both the C-CAT and S-CAT.
- •Has a visible or large pocket of submental fat- according to physician global assessment.
- •Has stable weight, with no fluctuation of >5 kg in the past 12 months.
- •If female, is not pregnant or breastfeeding based on the following:
- •agree to the use of highly effective contraceptive methods for at least 2 weeks before baseline until 4 weeks after the last day of study drug and a negative serum pregnancy test (ß-hCG) at screening and negative urine pregnancy test at baseline; or
- •is of nonchildbearing potential defined as clinically infertile as the result of surgical sterilization (hysterectomy, bilateral tubal ligation, and/or bilateral oophorectomy); or
- •is confirmed postmenopausal status (defined as either having amenorrhea for ≥ 12 consecutive months without another cause and documented serum follicle-stimulating hormone (FSH) level > 40 mIU/mL or another documented medical condition (e.g., was born without a uterus))
- •If male (with or without vasectomy), agree to the use of highly effective contraceptive methods as listed above in criteria 7 as well as to use a barrier method, e.g. condom , from study check-in until 7 days after the last day of study drug.
- •Is willing to avoid strenuous exercise for seven (7) days post treatment.
- •Is able to adhere to the visit schedule and protocol requirements and be available to complete the study.
- •Is willing and able to sign an Institutional Review Board (IRB) approved informed consent form (ICF) indicating that they are aware of the investigational nature of the study.
排除标准
- •Is unable to tolerate subcutaneous injections.
- •Has dysfunctional gallbladder activity (e.g., underwent cholecystectomy or cholecystitis).
- •Has any uncontrolled systemic disease that is not stabilized (i.e., cardiovascular disease, mental illness).
- •Has skin laxity (i.e., elastosis, skin crepiness, skin redundancy, skin draping, vertical and/or horizontal skin bands and folds, blunting of cervical mental angle, loss of opposition of skin to underlying neck structures due to skin laxity) that could obscure the evaluation and treatment of SMF.
- •Has any scars, unshaven hair, tattoos, facial hair or jewelry on or near the proposed treatment area.
- •Has presence of structures or confounding factors that may interfere with assessing SMF such as but not limited to enlarged submandibular salivary and/or parotid glands, micrognanthia, chin implant, soft tissue volume augmentation of chin and/or jawline, pronounced platysmal bands and deep necklace lines or presence of facial jowls that could obscure the evaluation of SMF.
- •Has a fat bulge under the chin that is too large to be adequately treated by 32±4 contiguous injections on a 1cm grid .
- •Has a fat bulge under the chin that is of an insufficient volume to allow 32±4 injections within a contiguous 1 cm grid.
- •Has significant history or current evidence of a medical, psychological or other disorder that, in the Investigator's opinion, would preclude enrollment in the study.
- •Has an active bacterial, fungal, or viral infection in the proposed treatment area.
- •Has a pre-existing skin condition in the submental region that, at the Investigator's discretion, may confound evaluation or analysis.
- •Has previously had treatments or surgery in the submentum, such as but not limited to, focused ultrasound, radiofrequency, cryolipolysis, liposuction, sodium deoxycholate, or neck lift.
- •Has pre-existing neurological or gastrointestinal condition leading to dysphagia, dysphonia, or facial nerve palsy.
- •Has Dercum's Disease.
- •Has allergic reactions to injectables.
- •Has any pre-existing medical condition other than increased SMF that, at the Investigator's discretion, may result in increased submental fullness, such as but not limited to, thyroid enlargement, goiter, cervical lymphadenopathy, etc.
- •Has a planned fat reduction procedure of any variety to the submental region for the duration of the study.
- •Has medication or a history of coagulopathy.
- •Has a history or family history of venous thrombotic disease.
- •Has been treated chronically at least three (3) months prior to study entry with systemic steroids or immunosuppressive drugs.
- •Has been treated chronically at least one (1) week prior to study entry with non-steroidal anti-inflammatory drugs (NSAIDs)
- •Has used anticoagulation therapies that may increase bleeding or bruising (i.e., aspirin, ibuprofen, warfarin, vitamins, and herbal preparations) for seven (7) days prior to treatment.
- •Has had treatment with botulinum toxin injections in the neck or chin area within 9 months prior to screening.
- •Current participation or participation within three (3) months prior to the start of this study in a drug or other investigational research study.
研究组 & 干预措施
RZL-012 50mg/ml
Experimental
small synthetic molecule for submental fat reduction
干预措施: RZL-012 (Drug)
结局指标
主要结局
Pharmacokinetics Measure - Drug Concentration in the Blood (ng/mL)
时间窗: 48 hours
Measurement of maximum drug concentration (Cmax) (ng/mL)
Pharmacokinetics Measure - Area Under the Plasma Concentration Versus Time Curve (AUC) (mg*h/L)
时间窗: 48 hours
次要结局
- Efficacy -Change in Score According to Clinician Chin Assessment Tool (C-CAT)(84 days)
- Efficacy - Change in Score According to Subject Chin Assessment Tool (S-CAT)(84 days)
- Efficacy - Change in Submental Fat Thickness(84 days)
- Safety - Adverse Events Follow up(84 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous ThromboembolismCancer-associated ThrombosisDuodenal CancerEsophagogastric Junction CancerMalignant Gastrointestinal Stromal TumorAmpulla of Vater CancerBiliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)Hepatocellular CarcinomaPancreatic CancerEsophageal CancerStomach CancerNCT03139487Asan Medical Center176
Unknown
2 期
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis bChronic Hepatitis bNCT04157699Qilu Pharmaceutical Co., Ltd.100
Unknown
2 期
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) TherapyChronic Hepatitis bNCT04157257Qilu Pharmaceutical Co., Ltd.60
已完成
2 期
Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal CancerGastric CancerNCT02725424Chinese Academy of Medical Sciences180
已完成
2 期
Efficacy and Tolerability of ZD6474 in Patients With Thyroid CancerThyroid CancerNCT00098345Genzyme, a Sanofi Company40